This report provides a comprehensive overview of the size of the microbiome therapeutic and diagnostic market, segmentation of the market (Gastrointestinal, Metabolic, Cancer, Neurological, Autoimmune, Skin), key players and the potential of therapies that are in clinical trials.
The analysis indicates that the global microbiome therapeutic and diagnostic market is worth $1.13 billion in 2018 and will grow at a CAGR of 19.03% over five years to $2.7 billion in 2023. The majority of the market will be dominated by microbiome based therapeutics, with an estimate of 90%, compared to 10% in microbiome diagnostics.
This report describes the evolution of such a prospective market in eight chapters supported by over 82 tables and figures in 165 pages.
Key Points Covered:
- An overview of the human microbiome space that includes how the market is sub-divided into therapeutics (prebiotics, probiotics, fecal microbiota transplantation, small molecules) and diagnostics.
- Global microbiome market, global breakdown, application breakdown and leading market players
- Detailed account of the microbiome industry market by geography, indication and company profiles
- Profiles, pipeline products, financial analysis and business strategy of the major companies in this space
- Focus on current trends, business environment, pipeline products, clinical trials, and future market forecast for microbiome therapeutics and diagnostics
- Insight into the challenges faced by stakeholders
- Insight into the biobanking industry globally and its impact on the overall market
- Description and data for the prevalence of disease types that are addressed by harnessing the human microbiota
- Financial market forecast through 2023 with CAGR values of all market segments outlined in the objective
- SWOT analysis of the global market
- Geographical analysis and challenges within key topographies including North America, Europe, Asia/Pacific, Middle East/Africa, ROW
Key Questions Answered:
- What are the Main Microbiome Therapeutics in the Pipeline?
- What are the Main Microbiome Diagnostics in the Pipeline?
- What Key Biologics are in the Pipeline?
- How Many Human Therapeutic and Diagnostic Microbiome Products are in the Pipeline?
- What is the Human Therapeutic Pipeline like by Drug, Company and Stage of Development?
- What Microbiome Therapeutics are in the Clostridium Difficile Infection Pipeline?
- Who are the Major Players in the Therapeutic and Diagnostic Spaces?
- What will the Microbiome Therapeutic Market be Worth in 2023?
- What will the Microbiome Therapeutic Sub-Markets (Gastrointestinal, Metabolic, Cancer, Neurological, Autoimmune, Skin) be Worth in 2023?
- What will the Microbiome Diagnostic Market be Worth in 2023?
- What will the Microbiome Diagnostic Sub-Markets (Gastrointestinal, Metabolic, Cancer, Neurological, Autoimmune, Skin) be Worth in 2023?
- What are the Main Drivers, Threats and Opportunities of these Markets?
- What were the Most Influential Market Deals to Date?
- How Much Venture Capital has Been Invested in the Microbiome Industry?
- What Major Microbiome Companies have Received Investment?
- What Microbiota are Associated with Cancer Development?
- How does Gut Dysbiosis influence the Host Inflammatory Response?
- Is there an Association Between the Development of Diabetes and Our Microbiota?
- How does Clostridium difficile Infection Impact the Microbiome?
- What Host-Microbe Interactions Occur During the Pathogenesis of Dental Caries?
- During Cirrhosis of the Liver, What Brain Dysfunction Occurs Due to Gut Dysbiosis?
- What are the Main Therapeutic Intervention Strategies for Microbiome Dysbiosis
- What Safety Requirements are Needed for Microbiome Therapeutics?
- What Clinical Trials are Investigating Probiotics and Obesity?
- What Clinical Trials are Investigating Probiotics and Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease?
- What Clinical Trials are Investigating Probiotics and Irritable Bowel Syndrome?
- What Clinical Trials are Investigating Probiotics and Obesity?
- How Has the Human Microbiome Project Investigated IBD, Prediabetes and Pregnancy?
Table of Contents
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4D Pharma
- Abbvie
- Allergan
- Assembly Biosciences
- Bristol Myers Squibb
- C3J Therapeutics
- Da Volterra
- Enterome
- Finch Therapeutics
- Immuron
- Matrisys Bioscience
- Merck
- Osel
- Pfizer
- Quorum Innovations
- Rebiotix
- Second Genome
- Seres Therapeutics
- Synlogic
- Synthetic Biologics
- Takeda
- Vedanta Biosciences
Methodology
Based on Locations in Europe and Asia, the analyst team are all PhD-level experts and industry-experienced professionals. They pool resources, contacts, business acumen, and technical experience to provide cutting edge insights for all of the reports. The senior analysts have at least ten years’ experience in major strategic corporations such as BCC research and TriMarkPublications. The methodologies are clearly defined from the outset. Initially, a number of clear objectives are set, e.g., to identify the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments:
- By Company
- By Geography (US, UK, EU, Asia)
- By Segment
- By Sub-market
Key Strengths, Weaknesses and Threats InfluencingLeading Player Position within the Market
- Technologies Driving the Market
- Top Fastest Growing Market Segments and Emerging Opportunities
- Top Pharmaceutical Companies within the IPM by Market Share and Revenue
- Comprehensive Product Portfolios, R&D Activity, and Pipeline Therapeutics
- M&A Activity and Future Strategies of Top Personalized Medicine Pharmacos
Following this, the analyst determines key financial data & business strategy information to give clients the most accurate information required to identify areas of profitable growth and what technical advantages are required in a competitive landscape such as company financials, sales & revenue figures.
Market analysis is initiated using primary research tools such as speaking directly with end-users, identifying their needs, and any un-met needs in the market place. This exploratory research identifies any specific requirements in the market and is tailored specifically to niche markets such as gene therapy, regenerative medicine, personalized medicine, targeted therapeutics and companion diagnostics, drug delivery systems, cosmetic surgery and services, cancer biomarkers and immunotherapy. At KellyScientific, we have a wide range of contacts within these niche areas that provide us with cutting edge insights into a marketplace that is beyond the reach of many. We also travel to international conferences quarterly to source new data and trends from global experts.
Secondary research performed by Kelly Scientific is meticulously scrutinized and analysed prior to integration into a final report. We only use validated and confirmed sources of information from company-specific corporate websites, government websites and documents, annual reports, press releases, international peer-reviewed scientific and medical journals, and research reports. Together both primary and secondary research and also unique insights from the chief analysts and editor alike provide the client with a report that exceeds its competitors.
LOADING...
![Human Microbiome Market: Trends, Forecast and Competitive Analysis [2024-2030] - Product Image](http://www.researchandmarkets.com/product_images/12371/12371581_60px_jpg/human_microbiome_market_[20242030].jpg)
